Intercept’s Ocaliva (obeticholic acid) is under review in the potentially lucrative fatty liver disease non-alcoholic steatohepatitis (NASH), making it a potential first-to-market drug in the indication – but there are plenty of other contenders who hope to muscle in on this likely multi-billion dollar market too.
One of the smaller players is the French biotech Poxel, but the company’s management told those attending the Jefferies London Healthcare Conference that the firm intends to keep a watching brief on how some of the bigger companies fare.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,